NXGL
NEXGEL, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$0.32
−6.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 12.1M | 11.4M | 8.7M | 4.1M | 2.0M |
| Cost of Revenue | 7.8M | 6.9M | 5.9M | 3.7M | 1.8M |
| Gross Profit | 4.2M | 4.5M | 2.7M | 374.0K | 256.0K |
| Operating Expenses | |||||
| R&D Expense | 27.0K | 2.0K | 78.0K | 103.0K | 367.0K |
| SG&A Expense | 9.5M | 7.9M | 5.9M | 3.4M | 2.8M |
| General & Admin Expense | 4.8M | — | 3.7M | 3.0M | 2.4M |
| Selling & Marketing Expense | 650.0K | — | 2.2M | 440.0K | 436.0K |
| Other Expenses | 80.0K | — | 313.0K | 350.0K | 421.0K |
| Total Operating Expenses | 9.6M | 7.9M | 6.3M | 3.9M | 3.6M |
| Cost and Expenses | 17.5M | 14.8M | 12.2M | 7.6M | 5.4M |
| Operating Income (EBIT) | (5.4M) | (3.4M) | (3.6M) | (3.5M) | (3.3M) |
| Non-Operating | |||||
| Interest Income | 10.0K | — | — | — | — |
| Interest Expense | 2.2M | 34.0K | 81.0K | 15.0K | 1.3M |
| Net Interest Income | (2.2M) | (34.0K) | (81.0K) | (15.0K) | (1.3M) |
| Other Non-Op Income/Expense | (650.0K) | 459.0K | 91.0K | 289.0K | (1.4M) |
| Non-Operating Income (excl Interest) | (1.6M) | (493.0K) | (172.0K) | (304.0K) | 62.0K |
| EBT (Pre-Tax Income) | (6.1M) | (2.9M) | (3.5M) | (3.2M) | (4.7M) |
| Income Tax Expense | 56.0K | — | — | — | — |
| Bottom Line | |||||
| Net Income | (6.2M) | (3.0M) | (3.3M) | (3.2M) | (4.7M) |
| Earnings from Cont. Ops | (6.1M) | (2.9M) | (3.5M) | (3.2M) | (4.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (6.2M) | (3.0M) | (3.3M) | (3.2M) | (4.7M) |
| Per Share | |||||
| Basic EPS | ($0.71) | ($0.38) | ($0.50) | ($0.56) | ($0.85) |
| Diluted EPS | ($0.71) | ($0.38) | ($0.50) | ($0.56) | ($0.85) |
| Revenue Per Share | $1.34 | $1.45 | $1.33 | $0.72 | $0.37 |
| Shares | |||||
| Basic Shares Outstanding | 9.0M | 7.9M | 6.5M | 5.7M | 5.6M |
| Diluted Shares Outstanding | 9.0M | 7.9M | 6.5M | 5.7M | 5.6M |
| Profitability Metrics | |||||
| EBITDA | (2.1M) | (2.1M) | (2.9M) | (2.7M) | (3.1M) |
| D&A | 1.7M | 740.0K | 480.0K | 443.0K | 301.0K |
| EBIT | (3.8M) | (2.9M) | (3.4M) | (3.2M) | (3.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026